Washington spends enormous energy scrutinizing the policy positions of FDA commissioner nominees. But does it pay enough attention to whether they can ...
The political action committees of the 10 largest drugmakers by 2025 global pharmaceutical sales, along with PhRMA and BIO, directed nearly all their ...
A single trading day offers limited evidence, but Friday’s sharp divergence between tech and large-cap biopharma stocks suggests the latter could ...
FDA has at least eleven PDUFA dates on its November calendar, 10 of which are for new products. First up is PD-1 x VEGF ...
Only about 5% of rare diseases have an approved therapy, and this is unlikely to change without novel development processes.
Gilde’s Impact Council as a multi-stakeholder diligence engine — Former regulators, HTA leaders, payers, clinicians, and ...
For more than a decade, it has been clear that U.S. clinical trials are too slow, too costly, and too far removed from the ...
The growing trend of co-development, co-commercialization deals may get cut in its prime if the COINS Act is finalized as ...
Two-thirds of China-to-West NewCo deals since 2023 have included a disclosed equity component. Treasury’s proposed ...
Antibody-drug conjugates accounted for more first-in-human studies than any other modality at ESMO 2026, highlighting their ...
STING agonists, drugs that trigger an immune alarm inside cells, have repeatedly failed in clinical trials despite shrinking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results